---
title: "Avanos Medical | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 182.2 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285192213.md"
datetime: "2026-05-05T11:02:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285192213.md)
  - [en](https://longbridge.com/en/news/285192213.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285192213.md)
---

# Avanos Medical | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 182.2 M

Revenue: As of FY2026 Q1, the actual value is USD 182.2 M, beating the estimate of USD 170 M.

EPS: As of FY2026 Q1, the actual value is USD 0.11.

EBIT: As of FY2026 Q1, the actual value is USD 10.2 M.

Avanos Medical, Inc. reported its financial results for the first quarter of 2026, including key operational and financial metrics across its segments .

#### Overall Financial Performance

-   **Total Net Sales**: Total net sales for the first quarter of 2026 were $182.2 million, representing an 8.8% increase compared to the prior year period .
-   **Net Income**: The company reported net income of $5.1 million for Q1 2026, which is a decrease from $6.6 million in the prior year .
-   **Adjusted Net Income**: Adjusted net income was $10.6 million, down from $12.0 million a year ago .
-   **Adjusted EBITDA**: Adjusted EBITDA for Q1 2026 was $21.8 million, slightly up from $21.6 million in the prior year .
-   **Operating Income**: Total operating income for the quarter was $8.9 million, compared to $10.3 million in the prior year .
-   **Gross Profit**: Gross profit was $94.2 million in Q1 2026, compared to $89.8 million in Q1 2025 .
-   **Gross Profit Margin**: The reported gross profit margin was 51.7%, while the adjusted gross profit margin was 53.4% . In Q1 2025, the reported gross profit margin was 53.6%, and the adjusted gross profit margin was 56.7% .

#### Segment Revenue and Operational Metrics

-   **Specialty Nutrition Systems (SNS) Segment**: This segment delivered net sales of $124.0 million in Q1 2026, an increase of $22.9 million compared to the prior year period . The total net sales percentage change for SNS was 22.7%, driven by 19.0% volume, 1.4% pricing/mix, and 2.8% currency . Operating income in the SNS segment was $23.1 million, or 18.6% of SNS net sales, an increase of $2.0 million over the prior year .
-   **Pain Management & Recovery (PM&R) Segment**: Net sales for the PM&R segment were $56.3 million in Q1 2026 . Overall PM&R net sales growth was relatively flat compared to the prior year period, with a total net sales percentage change of 0.2%, including 3.2% volume, 0.1% pricing/mix, 1.0% currency, and -4.1% from other factors . The PM&R segment reported an operating loss of -$1.8 million, compared to an operating income of $0.2 million in the prior year .

#### Cash Flow and Balance Sheet

-   **Cash Flow from Operating Activities**: Cash used in operations for the three months ended March 31, 2026, was -$12.3 million, a decrease from cash flow provided by operations of $25.7 million in the prior year .
-   **Free Cash Flow**: Free cash flow for Q1 2026 was an outflow of -$16.6 million, compared to an inflow of $19.0 million in the prior year .
-   **Cash and Cash Equivalents**: As of March 31, 2026, the cash balance was $65.6 million, down from $97.0 million a year ago and $89.8 million as of December 31, 2025 .
-   **Total Debt**: Total debt at the end of the first quarter was $98.2 million, primarily from the Company’s term loan facility .

#### Unique Metrics and Strategic Developments

-   Avanos Medical, Inc. announced the execution of a definitive agreement on April 14, 2026, to be acquired by certain affiliates of American Industrial Partners in an all-cash offer at an enterprise value of $1.272 billion .

#### Outlook / Guidance

-   The provided reference does not contain any outlook or guidance content .

### Related Stocks

- [AVNS.US](https://longbridge.com/en/quote/AVNS.US.md)

## Related News & Research

- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [The Seed 40: The best women early-stage investors of 2026](https://longbridge.com/en/news/286743171.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [Keysight Technologies Reports Second Quarter 2026 Results | KEYS Stock News](https://longbridge.com/en/news/286959830.md)
- [GE Vernova Declares Third Quarter 2026 Dividend | GEV Stock News](https://longbridge.com/en/news/286966387.md)